Structure Therapeutics, Inc. Sponsored ADR ( (GPCR) ) has released its Q3 earnings. Here is a breakdown of the information Structure ...

Structure Therapeutics (GPCR) announced the first patients have been dosed in the randomized, double-blind, placebo-controlled Phase 2b ACCESS ...

Phase 2 trial initiation in patients with sleep /wake disorders results in milestone payment of US$3.5 million to Nxera Tokyo ...

This unique cocrystal composition offers a novel approach to mental health treatment. ART27.13 is a G-Protein Coupled ...

Nxera Pharma has entered a collaboration and licensing agreement with Antiverse to design antibodies for GPCRs.

Nxera Pharma & Antiverse collaborate to design novel GPCR-targeted antibody therapeutics using generative AI: Tokyo, Japan Wednesday, November 6, 2024, 13:00 Hrs [IST] Nxera Pharm ...

have today announced a multi-target partnership and licensing agreement to design antibodies for G-protein coupled receptors (GPCRs). The company noted that the collaboration combines Antiverse’s ...

ORs are members of the superfamily of membrane-bound proteins known as G-protein-coupled receptors (GPCRs), which typically respond to a stimulus in a cell’s environment by engaging with G ...

G protein-coupled receptors (GPCRs) are the largest and most diverse group of membrane receptors in the body. They are responsible for many physiological responses in the body and are attractive drug ...

AST-004 is a small-molecule adenosine A1/A3 receptor agonist that has exhibited significant cerebroprotective efficacy in preclinical models of acute ischemic stroke and traumatic brain injury. The ...

Interest in Septerna, which came out of stealth in January 2022, has been sparked by its development of G protein-coupled receptors (GPCRs). Using a platform for isolating functional native GPCR ...